Annual report [Section 13 and 15(d), not S-K Item 405]

IN-LICENSING AND ACQUISITION - Narrative (Details)

v3.25.0.1
IN-LICENSING AND ACQUISITION - Narrative (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Feb. 22, 2024
Jul. 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Asset Acquisition [Line Items]          
Acquisition-related liabilities     $ 5,000    
Intangible assets, estimated useful life     11 years 6 months 14 days    
Research and development     $ 23,380 $ 24,522 $ 60,272
Intangible asset     $ 27,100 $ 13,878  
Forma          
Asset Acquisition [Line Items]          
Upfront fee         2,000
Research and development         2,000
Forma | Commercial milestones          
Asset Acquisition [Line Items]          
Potential payments         165,500
Forma | Development and regulatory milestones          
Asset Acquisition [Line Items]          
Potential payments         67,500
Forma | Achievement of certain near-term regulatory milestone          
Asset Acquisition [Line Items]          
Research and development         $ 2,500
GAVRETO (pralsetinib)          
Asset Acquisition [Line Items]          
Intangible assets, estimated useful life     12 years    
Asset purchase agreement, drug product inventories     $ 6,500    
REZLIDHIA          
Asset Acquisition [Line Items]          
Intangible assets, estimated useful life     14 years    
Blueprint          
Asset Acquisition [Line Items]          
Acquisition payment $ 15,000        
Blueprint | GAVRETO (pralsetinib)          
Asset Acquisition [Line Items]          
Asset acquisition, expected price $ 15,000        
Acquisition-related liabilities     $ 5,000    
Acquisition payment   $ 10,000      
Blueprint | GAVRETO (pralsetinib) | Minimum          
Asset Acquisition [Line Items]          
Potential tiered royalties (as a percentage) 10.00%        
Blueprint | GAVRETO (pralsetinib) | Maximum          
Asset Acquisition [Line Items]          
Potential tiered royalties (as a percentage) 30.00%        
Blueprint | GAVRETO (pralsetinib) | First commercial sale          
Asset Acquisition [Line Items]          
Asset acquisition, expected price $ 10,000        
Blueprint | GAVRETO (pralsetinib) | First anniversary of the closing date          
Asset Acquisition [Line Items]          
Asset acquisition, expected price 5,000        
Blueprint | GAVRETO (pralsetinib) | Commercial milestones          
Asset Acquisition [Line Items]          
Potential milestone payments 97,500        
Blueprint | GAVRETO (pralsetinib) | Regulatory milestones          
Asset Acquisition [Line Items]          
Potential milestone payments $ 5,000